LBA29 Individualized starting dose of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC): A randomized, double-blind, placebo-controlled, phase III trial (NORA)

• DOI: 10.1016/j.annonc.2020.08.2259
• Publication Date: 2020-09-22T09:18:00Z
• Authors: X. Wu; J. Zhu; R. Yin; J. Yang; J. Liu; J. Wang; L. Wu; Z. Liu; Y. Gao; D. Wang; G. Lou; H. Yang; Q. Zhou; B. Kong; Y. Huang; L. Chen; G. Li; R. An; K. Wang; Y. Zhang
• Keywords: 03 medical and health sciences; 0302 clinical medicine